Most of the major players in the medical device arena, and a few from off the bench, are busy touting new products
and results from a slew of clinical trials at the European Assn. of
Percutaneous Cardiovascular Interventions annual conference, EuroPCR 2010:

Abbott (NYSE:ABT):

• New Data Reinforces Safety Profile of
  Abbott’s Market-Leading XIENCE V Drug Eluting Stent:

  In XIENCE V USA Study, XIENCE V Demonstrates Low Blood Clot Rate
  at One Year in Real-World Patient Population;

  In SPIRIT V Diabetes Trial, XIENCE V Demonstrates Zero Cases of
  Stent Thrombosis at One Year in Patients with Diabetes

• Abbott’s Investigational MitraClip
  System Demonstrates Strong Safety Results and Improved Clinical
  Outcomes for Common Causes of Leaky Heart Valves:

  Preliminary Results Also Show MitraClip Device Maintains
  Durability through Two Years in Patients Treated for Mitral
  Regurgitation

• Abbott’s Groundbreaking Bioresorbable
  Technology Continues to Demonstrate Exceptional Clinical
  Results:

  New Six-Month Data on Abbott’s Bioresorbable Vascular Scaffold
  Reinforces Its Potential to Be the Next Revolution in
  Interventional Cardiology

Abiomed Inc. (NSDQ:ABMD):

• Abiomed Reports Updated USpella Results
  Presented at EuroPCR 2010:

  52% of patients improved New York Heart Association (NYHA)
  classification by one or more categories after Impella-supported
  complex PCI. Prior to treatment, 63% of patients were in NYHA class
  three or four. After treatment, 70% were in NYHA class one or
  two.

Cordis Corp. [Johnson & Johnson
(NYSE:JNJ)]:

• NEVO Sirolimus-Eluting Coronary Stent
  Continues to Demonstrate Excellent Safety and Efficacy Outcomes in
  New Twelve-Month Data:

  NEVO, Incorporating RES TECHNOLOGY, Continues to Support Excellent
  Safety and Efficacy Outcomes vs. the Taxus Liberte According to
  Data Presented at EuroPCR 2010

InspireMD Ltd.:

• InspireMD Will Provide a Sneak
  Preview of the Next Generation MGuard Prime, a State of the Art Net
  Protective Cobalt Chromium Stent System:

  InspireMD is Also Proud to Announce That MGuard is Now Available
  With an Improved Delivery System. Final 6 Month Results of the
  MAGICAL Trial and Final 1 Year Results of the INSPIRE Study Will be
  Presented During EuroPCR 2010

Medtronic Inc. (NYSE:MDT):

• Medtronic CoreValve System Shows
  Long-Term Efficacy and Durability in Pivotal Trial:

  Market-Leading Transcatheter Aortic Valve Delivers Positive
  Clinical Outcomes Through Two Years in Major International Study;
  Achieves 10,000-patient Milestone

• Multiple European Clinical Registries
  Show Important Benefits of Medtronic CoreValve Transcatheter Aortic
  Valve System:

  Data Demonstrates That Revolutionary Treatment for Patients with
  Diseased Heart Valves Is Transitioning Successfully into Standard
  Clinical Practice throughout Europe

• Medtronics Resolute Drug-Eluting Stent
  Matches Market-Leading Rival in Large Head-to-Head Study:

  One-Year Clinical Results from Innovative RESOLUTE All Comers Trial
  Show Excellent Performance for Resolute DES in Challenging Patient
  Population

NMT Medical Inc. (NSDQ:NMTI):

• NMT Medical Launches Rapid Transport
  Septal Implant Delivery System in France:

  Enhancement Allows Easier Implantation of BioSTAR and STARFlex
  Devices

NovoStent Corp.:

• NovoStent Announces 6-Month
  Results of SAMBA Femoropopliteal Trial:

  The SAMBA data showed a 97% Freedom from Target Lesion
  Revascularization rate. There were no device related complications
  in any of the 38 patients treated in the trial.

OrbusNeich:

• Data Presented at EuroPCR 2010
  Demonstrate Effectiveness of OrbusNeich’s Genous” Bio-engineered R
  stent” in Diabetic Patients:

  OrbusNeich today announced that 12-month follow-up data from a
  subset analysis of the global e-HEALING registry demonstrate that
  the company’s Genous Bio-engineered R stent is effective in
  diabetic patients.

St. Jude Medical Inc. (NYSE:STJ):

• St. Jude Medical Announces Initiation of
  a Study to Evaluate the Economic Impact of FFR in Europe and
  Canada:

  Country-specific analysis will evaluate the cost effectiveness of
  an FFR-guided intervention strategy for patients with multivessel
  coronary artery disease in the UK, Germany, France, Italy,
  Switzerland, Belgium and Canada; Unique data from each country will
  be used to assess the budget and health impact of FFR on its health
  care system

Tryton Medical Inc.:

• Tryton Announces Positive Data from
  Side Branch System Presented in Symposium at EuroPCR
  2010:

  Tryton Stent Consistently Demonstrates Excellent Results

SOURCE